Abstract:Background: Iron oxide nanoparticles (IONPs) have been cleared by the Food and Drug Administration (FDA) for various clinical applications, such as tumor-targeted imaging, hyperthermia therapy, drug delivery, and live-cell tracking. However, the application of IONPs as T1 contrast agents has been restricted due to their high r2 values and r2/r1 ratios, which limit their effectiveness in T1 contrast enhancement. Notably, IONPs with diameters smaller than 5 nm, referred to as extremely small-sized IONPs (ESIONs), have demonstrated potential in overcoming these limitations. To advance the clinical application of ESIONs as T1 contrast agents, we have refined a scale-up process for micelle encapsulation aimed at improving the hydrophilization of ESIONs, and have carried out comprehensive in vivo biodistribution and preclinical toxicity assessments. Results: The optimization of the scale-up micelle-encapsulation process, specifically employing Tween60 at a concentration of 10% v/v, resulted in ESIONs that were uniformly hydrophilized, with an average size of 9.35 nm and a high purification yield. Stability tests showed that these ESIONs maintained consistent size over extended storage periods and dispersed effectively in blood and serum-mimicking environments. Relaxivity measurements indicated an r1 value of 3.43 mM- 1s- 1 and a favorable r2/r1 ratio of 5.36, suggesting their potential as T1 contrast agents. Biodistribution studies revealed that the ESIONs had extended circulation times in the bloodstream and were primarily cleared via the hepatobiliary route, with negligible renal excretion. We monitored blood clearance and organ distribution using positron emission tomography and magnetic resonance imaging (MRI). Additionally, MRI signal variations in a dose-dependent manner highlighted different behaviors at varying ESIONs concentrations, implying that optimal dosages might be specific to the intended imaging application. Preclinical safety evaluations indicated that ESIONs were tolerable in rats at doses up to 25 mg/kg. Conclusions: This study effectively optimized a scale-up process for the micelle encapsulation of ESIONs, leading to the production of hydrophilic ESIONs at gram-scale levels. These optimized ESIONs showcased properties conducive to T1 contrast imaging, such as elevated r1 relaxivity and a reduced r2/r1 ratio. Biodistribution study underscored their prolonged bloodstream presence and efficient clearance through the liver and bile, without significant renal involvement. The preclinical toxicity tests affirmed the safety of the ESIONs, supporting their potential use as T1 contrast agent with versatile clinical application.

Moderate Cooling Coprecipitation for Extremely Small Iron Oxide As a Ph Dependent T1-MRI Contrast Agent.

Continuous Synthesis of Extremely Small-Sized Iron Oxide Nanoparticles Used for T1-weighted Magnetic Resonance Imaging Via a Fluidic Reactor

2, 3-Dimercaptosuccinic Acid-Modified Iron Oxide Clusters for Magnetic Resonance Imaging

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Exceedingly Small Magnetic Iron Oxide Nanoparticles for T1‐Weighted Magnetic Resonance Imaging and Imaging‐Guided Therapy of Tumors

Extremely Small Iron Oxide Nanoparticles with Ph-Dependent Solubility Transition As T1/T2 Switchable Contrast Agents for MRI

A T1/T2 dual functional iron oxide MRI contrast agent with super stability and low hypersensitivity benefited by ultrahigh carboxyl group density

Highly Sensitive T-1-T-2 Dual-Mode Mri Probe Based On Ultra-Small Gadolinium Oxide-Decorated Iron Oxide Nanocrystals

Ultrasmall Water‐Soluble and Biocompatible Magnetic Iron Oxide Nanoparticles As Positive and Negative Dual Contrast Agents

Precise Study on Size-Dependent Properties of Magnetic Iron Oxide Nanoparticles for in Vivo Magnetic Resonance Imaging

Ultrasmall Superparamagnetic Iron Oxide Nanoparticle for T2-Weighted Magnetic Resonance Imaging.

Optimization of micelle-encapsulated extremely small sized iron oxide nanoparticles as a T1 contrast imaging agent: biodistribution and safety profile

Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors

In Situ One-Pot Synthesis of Fe 2 O 3 @BSA Core-Shell Nanoparticles as Enhanced T 1 -Weighted Magnetic Resonance Imagine Contrast Agents

Synthesis of sub-100 nm biocompatible superparamagnetic Fe3O4 colloidal nanocrystal clusters as contrast agents for magnetic resonance imaging

Fe3O4 Nanoparticles Functionalized with Polymer Ligand for T-1-Weighted MRI in Vitro and in Vivo

Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging.

Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast<i>T</i><sub>1</sub>- and<i>T</i><sub>2</sub>-weighted magnetic resonance imaging

Ultrasmall Ferrite Nanoparticles Synthesized Via Dynamic Simultaneous Thermal Decomposition for High-Performance and Multifunctional T1 Magnetic Resonance Imaging Contrast Agent.

In Situ One-Pot Synthesis of Fe2O3@BSA Core-Shell Nanoparticles As Enhanced T1-Weighted Magnetic Resonance Imagine Contrast Agents

Hydrothermal synthesis of a highly sensitive T2-weigthed MRI contrast agent: zinc-doped superparamagnetic iron oxide nanocrystals.